Summary:
Arizona Research Center is conducting a phase 2b, randomized, double-blind, placebo-controlled study of LY2951742 (injection) in patients With episodic Migraines.
Eligibility:
- Ages Eligible for Study: 18 Years to 65 Years
- Male and Female
- Accepts Healthy Volunteers: No
Inclusion Criteria:
- Participants with a history of migraine of at least 1 year prior to enrollment
- Migraine onset prior to age 50
- more inclusion criteria apply
Exclusion Criteria:
- Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device
- Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF)
- History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilar-type migraine
- Have a history or presence of other medical illness that indicates a medical problem that would preclude study participation
- Failure to respond to more than two adequately dosed effective migraine prevention treatments
- Evidence of significant active psychiatric disease, in the opinion of the investigator
- Women who are pregnant or nursing
- More exclusion criteria apply
Qualified Participants May Receive:
Up to $1,000 compensation for time/travel.